

European
Innovation
Council



Co-funded by
the European Union

PHARMNOVO
Innovation in pain relief

CONFIDENTIAL

PHARMNOVO

ALMI Summit, October 2025

Per von Mentzer, CEO

LEAD CANDIDATE



CONFIDENTIAL

PN6047
PHASE II READY DRUG
FOR NEURO-
PATHIC PAIN

with first-in-class potential

THE OPPORTUNITY

CONFIDENTIAL

Neuropathic pain ruins people's lives

- Affects up to 10% of the adult population
- No effective treatments available
- Severe side effects from current medicines
- Neuropathic pain segment to reach \$13 billion in 2033



THE SOLUTION



CONFIDENTIAL

PN 6047 A NEW ERA IN TREATMENT OF NEURO- PATHIC PAIN


PN6047 is a novel DORA (delta opioid receptor agonist)
Effectively reduces neuropathic pain with allodynia and hyperalgesia
Safe and tolerable
First-in-class potential

PN6047 MECHANISM OF ACTION


PHARMNOVO
Innovation in pain relief

CONFIDENTIAL

Selective DORA




Biased DORA




POTENT AND SAFE

CONFIDENTIAL

Sustained pain relief



Safe and tolerable




PHASE I

CONFIDENTIAL

Exposure – predicted to be effective

240 mg TID, Fed



COMPANY

PHARMNOVO
Innovation in pain relief

CONFIDENTIAL

300 years
of drug development experience



Per von Mentzer
CEO



Bengt von Mentzer
Founder, CSA



Marianne Svärd
CMC sub-team lead



David Kendall
Professor, CSO



Alexander Dahlquist
CFO



Jesper Kjerulff
Project lead, COO



Petra Larson
Communications lead



Carl-Magnus Andersson
CMC lead



Jarkko Kalliomäki
MD, Clinical lead, CMO



Olof Breuer
MD, Clinical pharmacology lead



Kerstin Kenne
Toxicology lead



Stefan Ingelsson
Senior Clinical Trial Manager



Agusta Gudjonsdottir
Regulatory lead



Rikke Winther
Clinical outsourcing lead



Ann Christine Korsgaard
Regulatory affairs

STRATEGY AND ROADMAP

CONFIDENTIAL

2022 Q3

2025

2027

PHASE I
First studies in human

PHASE IIa
Proof of concept

PHASE IIb / PHASE III

Neuropathic Pain
(1-2 additional indications)

30 M€
(Series A 12M€ + B 18M€)

EIC grant

1 B€ at least
Potential exit deal value

INVESTMENT OPPORTUNITY

Invest in PharmNovo and PN6047

- EIC award validating PharmNovo as **top start-up** company
- Team with proven track records
- De-risked and differentiated asset with a **first-in-class** potential
- Potential for several additional high value indications
- Phase IIa ready with **block-buster** potential
- Exit potential by 2027/28 in excess of **1 billion €**
- Series A offer of 12 M€ - UCEA lead investor & term sheet available

European
Innovation
Council



Co-funded by
the European Union

PHARMNOVO
Innovation in pain relief

CONFIDENTIAL

THANK YOU FOR YOUR ATTENTION!



Disclaimer

GENERAL BACKGROUND INFORMATION

THE MATERIAL ON THIS SITE as well as all other material used in presentations or printed matters that have been prepared by PharmNovo AB, are general background information about PharmNovo's activities as at the date of the publication or presentation. The information is given in summary form and does not purport to be complete. All information, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to → holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice.

ALL SECURITIES AND FINANCIAL PRODUCT or instrument transactions involve risks, which include (among others) the risk of adverse, financial or political developments and other risks. material on this website or in presentations may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to PharmNovo's development opportunities and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward looking statements.

PHARMNOVO DOES NOT UNDERTAKE ANY OBLIGATION to publicly or otherwise release the result of any revisions to these forward looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events or the development of pharmaceutical compounds providing negative results. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside PharmNovo's control, past performance and achieved development milestones are not reliable indications of future performance. ■